Anti-Phospholipase A2 Receptor Autoantibodies

Monalyn De Los Reyes Labitigan, Chaim Putterman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.

Original languageEnglish (US)
Title of host publicationAutoantibodies: Third Edition
PublisherElsevier B.V.
Pages545-552
Number of pages8
ISBN (Print)9780444563781
DOIs
StatePublished - Dec 2013

Fingerprint

Phospholipase A2 Receptors
Nephritis
Autoantibodies
Antibodies
Research Personnel

Keywords

  • Anti-phospholipase A2 receptor antibodies
  • Lupus nephritis
  • Membranous nephropathy
  • Phospholipase A2 receptor
  • Podocytes
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Labitigan, M. D. L. R., & Putterman, C. (2013). Anti-Phospholipase A2 Receptor Autoantibodies. In Autoantibodies: Third Edition (pp. 545-552). Elsevier B.V.. https://doi.org/10.1016/B978-0-444-56378-1.00064-2

Anti-Phospholipase A2 Receptor Autoantibodies. / Labitigan, Monalyn De Los Reyes; Putterman, Chaim.

Autoantibodies: Third Edition. Elsevier B.V., 2013. p. 545-552.

Research output: Chapter in Book/Report/Conference proceedingChapter

Labitigan, MDLR & Putterman, C 2013, Anti-Phospholipase A2 Receptor Autoantibodies. in Autoantibodies: Third Edition. Elsevier B.V., pp. 545-552. https://doi.org/10.1016/B978-0-444-56378-1.00064-2
Labitigan MDLR, Putterman C. Anti-Phospholipase A2 Receptor Autoantibodies. In Autoantibodies: Third Edition. Elsevier B.V. 2013. p. 545-552 https://doi.org/10.1016/B978-0-444-56378-1.00064-2
Labitigan, Monalyn De Los Reyes ; Putterman, Chaim. / Anti-Phospholipase A2 Receptor Autoantibodies. Autoantibodies: Third Edition. Elsevier B.V., 2013. pp. 545-552
@inbook{8fed04b217ee44c1935be53bdd2c2df5,
title = "Anti-Phospholipase A2 Receptor Autoantibodies",
abstract = "Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.",
keywords = "Anti-phospholipase A2 receptor antibodies, Lupus nephritis, Membranous nephropathy, Phospholipase A2 receptor, Podocytes, Systemic lupus erythematosus",
author = "Labitigan, {Monalyn De Los Reyes} and Chaim Putterman",
year = "2013",
month = "12",
doi = "10.1016/B978-0-444-56378-1.00064-2",
language = "English (US)",
isbn = "9780444563781",
pages = "545--552",
booktitle = "Autoantibodies: Third Edition",
publisher = "Elsevier B.V.",

}

TY - CHAP

T1 - Anti-Phospholipase A2 Receptor Autoantibodies

AU - Labitigan, Monalyn De Los Reyes

AU - Putterman, Chaim

PY - 2013/12

Y1 - 2013/12

N2 - Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.

AB - Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.

KW - Anti-phospholipase A2 receptor antibodies

KW - Lupus nephritis

KW - Membranous nephropathy

KW - Phospholipase A2 receptor

KW - Podocytes

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84902064656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902064656&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-56378-1.00064-2

DO - 10.1016/B978-0-444-56378-1.00064-2

M3 - Chapter

AN - SCOPUS:84902064656

SN - 9780444563781

SP - 545

EP - 552

BT - Autoantibodies: Third Edition

PB - Elsevier B.V.

ER -